QTc prolongation is one of the possible complications in patients with schizophrenia taking antipsychotics, which leads to malignant cardiac arrhythmia. No meta-analysis has been reported assessing the prevalence and correlated risk factors for QTc prolongation.
Methods:
This meta-analysis aimed to assess the evidence for the prevalence of QTc prolongation and correlated risk factors in patients with schizophrenia taking antipsychotics. Web of Science and PubMed were searched according to preset strategy. The quality of research was assessed by the Newcastle–Ottawa Scale (NOS).
Results:
In all, 15 studies covering 15,540 patients with schizophrenia taking antipsychotics were included. Meta-analysis showed that the prevalence of QTc prolongation in patients with schizophrenia taking antipsychotics was about 4.0% (95% confidence interval (CI): 3.0%–5.0%, p < 0.001). The prevalence was about 4.0% in Asia (95%CI: 3.0%–6.0%, p < 0.001), about 5.0% in Europe (95%CI: 2.0%–7.0%, p < 0.001), and about 2.0% in America (95%CI: 1.0%–3.0%, p < 0.001). Sensitivity analyses indicated the robustness of the result. Publication bias analysis reported a certain publication bias (t = 3.37, p = 0.012). Meta-regression suggested that female and elderly patients were clinically associated with a higher prevalence of QTc prolongation. According to included studies, smoking, comorbidity of cardiovascular disease, and abnormal levels of high-density lipoprotein/low-density lipoprotein might be related to QTc prolongation in patients with schizophrenia taking antipsychotics.
Conclusions:
The prevalence of QTc prolongation in patients with schizophrenia taking antipsychotics was about 4.0%. Female and elderly patients were more likely to experience QTc prolongation. Close electrocardiogram monitoring was suggested in these at-risk populations.
AcciavattiTMartinottiGCorboM, et al. (2017) Psychotropic drugs and ventricular repolarisation: The effects on QT interval, T-peak to T-end interval and QT dispersion. J Psychopharmacol31: 453–460.
2.
AgelinkMWMajewskiTWurthmannC, et al. (2001) Effects of newer atypical antipsychotics on autonomic neurocardiac function: a comparison between amisulpride, olanzapine, sertindole, and clozapine. J Clin Psychopharmacol21: 8–13.
3.
AtmacaMYavuzkirMMermiO, et al. (2008) Effect of sertindole on QTc interval in patients with schizophrenia. Neurosci Lett442: 1–3.
4.
AuneDSchlesingerSNoratT, et al. (2018) Tobacco smoking and the risk of sudden cardiac death: a systematic review and meta-analysis of prospective studies. Eur J Epidemiol33: 509–521.
5.
BahaoddiniAFarrashbandiHSaadatM (2009) Genetic polymorphism of glutathione S-transferase T1 (GSTT1) and QT-interval in schizophrenia patients. J Mol Neurosci38: 173–177.
6.
BaileyMSCurtisAB (2002) The effects of hormones on arrhythmias in women. Curr Womens Health Rep2: 83–88.
7.
BarbuiCBighelliICarraG, et al. (2016) Antipsychotic dose mediates the association between polypharmacy and corrected QT interval. PLoS One11: e0148212.
8.
BeachSRCelanoCMNoseworthyPA, et al. (2013) QTc prolongation, torsades de pointes, and psychotropic medications. Psychosomatics54: 1–13.
9.
BudenholzerB (2019) Review: in multiepisode schizophrenia, most antipsychotic drugs improve symptoms; adverse effects vary by drug. Ann Intern Med171: Jc57.
10.
CaoHZhouYLiT, et al. (2021) The prevalence, risk factors and clinical correlates of QTc prolongation in Chinese hospitalized patients with chronic schizophrenia. Front Psychiatry12: 704045.
11.
Castro-TorresYCarmona-PuertaRKatholiRE (2015) Ventricular repolarization markers for predicting malignant arrhythmias in clinical practice. World J Clin Cases3: 705–720.
12.
ChongSAMythily, LumA, et al. (2003) Prolonged QTc intervals in medicated patients with schizophrenia. Hum Psychopharmacol18: 647–649.
13.
CorrellCUHarrisJFigenV, et al. (2011) Antipsychotic drug administration does not correlate with prolonged rate-corrected QT interval in children and adolescents: results from a nested case-control study. J Child Adolesc Psychopharmacol21: 365–368.
14.
De YangFWangXQLiuXP, et al. (2011) Sex difference in QTc prolongation in chronic institutionalized patients with schizophrenia on long-term treatment with typical and atypical antipsychotics. Psychopharmacology216: 9–16.
15.
DekkerJMCrowRSHannanPJ, et al. (2004) Heart rate-corrected QT interval prolongation predicts risk of coronary heart disease in black and white middle-aged men and women: the ARIC study. J Am Coll Cardiol43: 565–571.
16.
Del GiornoRGabuttiSTroianiC, et al. (2019) Association between HDL cholesterol and QTc interval: a population-based epidemiological study. J Clin Med8: 1527.
17.
DrussBG (2018) Can better cardiovascular care close the mortality gap for people with schizophrenia?JAMA Psychiatry75: 1215–1216.
18.
ElliottAMørkTJHøjlundM, et al. (2018) QTc interval in patients with schizophrenia receiving antipsychotic treatment as monotherapy or polypharmacy. CNS Spectr23: 278–283.
19.
EtchegoyenCVKellerGAMradS, et al. (2017) Drug-induced QT interval prolongation in the intensive care unit. Curr Clin Pharmacol12: 210–222.
20.
FuXLQianYJinXH, et al. (2023) Suicide rates among people with serious mental illness: a systematic review and meta-analysis. Psychol Med. 53: 351–361.
21.
GadaletaFLLloisSCSinisiVA, et al. (2008) [Corrected QT interval prolongation: a new predictor of cardiovascular risk in patients with non-ST-elevation acute coronary syndrome]. Rev Esp Cardiol61: 572–578.
22.
GastaldelliAFolliFMaffeiS (2010) Impact of tobacco smoking on lipid metabolism, body weight and cardiometabolic risk. Curr Pharm Des16: 2526–2530.
23.
GirardinFRGex-FabryMBerneyP, et al. (2013) Drug-induced long QT in adult psychiatric inpatients: the 5-year cross-sectional ECG Screening Outcome in Psychiatry study. Am J Psychiatry170: 1468–1476.
24.
GlassmanAHBiggerJTJr (2001) Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry158: 1774–1782.
25.
GoldenbergIJonasMTenenbaumA, et al. (2003) Current smoking, smoking cessation, and the risk of sudden cardiac death in patients with coronary artery disease. Arch Intern Med163: 2301–2305.
26.
GrandeIPonsABaezaI, et al. (2011) QTc prolongation: is clozapine safe? Study of 82 cases before and after clozapine treatment. Hum Psychopharmacol26: 397–403.
27.
HaddadPMAndersonIM (2002) Antipsychotic-related QTc prolongation, torsade de pointes and sudden death. Drugs62: 1649–1671.
28.
HaddadPMSharmaSG (2007) Adverse effects of atypical antipsychotics: Differential risk and clinical implications. CNS Drugs21: 911–936.
29.
HasanAFalkaiPLehmannI, et al. (2020) Schizophrenia. Dtsch Arztebl Int117: 412–419.
30.
HeLYuYZhangL, et al. (2022) A real-world study of risk factors for QTc prolongation in schizophrenia patients receiving atypical antipsychotics. J Clin Psychopharmacol42: 71–74.
31.
HeemskerkCPMPereboomMvan StralenK, et al. (2018) Risk factors for QTc interval prolongation. Eur J Clin Pharmacol74: 183–191.
32.
HuhnMNikolakopoulouASchneider-ThomaJ, et al. (2019) Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet394: 939–951.
33.
KameiH (2022) Polypharmacy management of antipsychotics in patients with schizophrenia. Medicina (Kaunas)58: 1584.
34.
KangUGKwonJSAhnYM, et al. (2000) Electrocardiographic abnormalities in patients treated with clozapine. J Clin Psychiatry61: 441–446.
35.
KimKKimYSJooEJ, et al. (2022) Clozapine blood concentration predicts corrected QT-interval prolongation in patients with psychoses. J Clin Psychopharmacol42: 536–543.
36.
KingMJonesRPetersenI, et al. (2020) Cigarette smoking as a risk factor for schizophrenia or all non-affective psychoses. Psychol Med51: 1373–1381.
37.
KirchhofPFabritzL (2011) High-density lipoprotein shortens the ventricular action potential. A novel explanation for how statins prevent sudden arrhythmic death?J Am Coll Cardiol58: 45–47.
38.
KunutsorSKZaccardiFKarppiJ, et al. (2017) Is high serum LDL/HDL cholesterol ratio an emerging risk factor for sudden cardiac death? Findings from the KIHD study. J Atheroscler Thromb24: 600–608.
39.
LiKJGreensteinAPDelisiLE (2018) Sudden death in schizophrenia. Curr Opin Psychiatry31: 169–175.
40.
LianJHuangXFPaiN, et al. (2014) Preventing olanzapine-induced weight gain using betahistine: a study in a rat model with chronic olanzapine treatment. PLoS One9: e104160.
41.
LinCHChenMCWangSY, et al. (2004) Predictive factors for QTc prolongation in schizophrenic patients taking antipsychotics. J Formosan Med Assoc103: 437–441.
42.
LinLChuH (2018) Quantifying publication bias in meta-analysis. Biometrics74: 785–794.
43.
MackinPYoungAH (2005) QTc interval measurement and metabolic parameters in psychiatric patients taking typical or atypical antipsychotic drugs: a preliminary study. J Clin Psychiatry66: 1386–1391.
44.
MartinottiGDe RisioLVanniniC, et al. (2021) Substance-related exogenous psychosis: a postmodern syndrome. CNS Spectr26: 84–91.
45.
MoherDAltmanDGSchulzKF, et al. (2004) Opportunities and challenges for improving the quality of reporting clinical research: CONSORT and beyond. CMAJ171: 349–350.
46.
MoradiHHarveyPDHelldinL (2018) Correlates of risk factors for reduced life expectancy in schizophrenia: is it possible to develop a predictor profile?Schizophr Res201: 388–392.
47.
MüllerMJRegenbogenBSachseJ, et al. (2006) Gender aspects in the clinical treatment of schizophrenic inpatients with amisulpride: a therapeutic drug monitoring study. Pharmacopsychiatry39: 41–46.
48.
NeumeierMSHomanSVetterS, et al. (2021) Examining side effect variability of antipsychotic treatment in schizophrenia spectrum disorders: a meta-analysis of variance. Schizophr Bull47: 1601–1610.
49.
NielsenJBGraffCRasmussenPV, et al. (2014) Risk prediction of cardiovascular death based on the QTc interval: evaluating age and gender differences in a large primary care population. Eur Heart J35: 1335–1344.
50.
NosèMBighelliICastellazziM, et al. (2016) Prevalence and correlates of QTc prolongation in Italian psychiatric care: cross-sectional multicentre study. Epidemiol Psychiatr Sci25: 532–540.
51.
OkayasuHShinozakiTTakanoY, et al. (2021) Effects of antipsychotics on arrhythmogenic parameters in schizophrenia patients: beyond corrected QT interval. Neuropsychiatr Dis Treat17: 239–249.
52.
OlsenREKrokenRABjorhovdeS, et al. (2016) Influence of different second generation antipsychotics on the QTc interval: a pragmatic study. World J Psychiatry6: 442–448.
53.
OzekiYFujiiKKurimotoN, et al. (2010) QTc prolongation and antipsychotic medications in a sample of 1017 patients with schizophrenia. Prog Neuro-Psychopharmacol Biol Psychiatry34: 401–405.
54.
PageMJMcKenzieJEBossuytPM, et al. (2021). The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. PLoS Med18(3): e1003583. doi: 10.1371/journal.pmed.1003583. PMID: 33780438; PMCID: PMC8007028.
55.
ParkS-CLeeBJParkJH, et al. (2020) QT interval prolongation noted in one percent of 2553 Asian patients with schizophrenia: findings from the REAP-AP survey. Kaohsiung J Med Sci36: 1030–1037.
56.
PasquierMPantetOHugliO, et al. (2012) Prevalence and determinants of QT interval prolongation in medical inpatients. Intern Med J42: 933–940.
57.
Plana-RipollOPedersenCBAgerboE, et al. (2019) A comprehensive analysis of mortality-related health metrics associated with mental disorders: a nationwide, register-based cohort study. Lancet394: 1827–1835.
58.
PolcwiartekCKragholmKHansenSM, et al. (2020) Electrocardiogram characteristics and their association with psychotropic drugs among patients with schizophrenia. Schizophr Bull46: 354–362.
59.
Ramos-RíosRArrojo-RomeroMPaz-SilvaE, et al. (2010) QTc interval in a sample of long-term schizophrenia inpatients. Schizophr Res116: 35–43.
60.
RayWAChungCPMurrayKT, et al. (2009) Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med360: 225–235.
61.
RijnbeekPRvan HerpenGBotsML, et al. (2014) Normal values of the electrocardiogram for ages 16–90 years. J Electrocardiol47: 914–921.
62.
RobbinsJNelsonJCRautaharjuPM, et al. (2003) The association between the length of the QT interval and mortality in the Cardiovascular Health Study. Am J Med115: 689–694.
63.
RobisonLBBradyWJRobisonRA, et al. (2021) QT interval prolongation and the rate of malignant ventricular dysrhythmia and cardiac arrest in adult poisoned patients. Am J Emerg Med46: 156–159.
64.
SadanagaTSadanagaFYaoH, et al. (2004) Abnormal QT prolongation and psychotropic drug therapy in psychiatric patients: significance of bradycardia-dependent QT prolongation. J Electrocardiol37: 267–273.
65.
SalaMVicentiniABrambillaP, et al. (2005) QT interval prolongation related to psychoactive drug treatment: a comparison of monotherapy versus polytherapy. Ann Gen Psychiatry4: 1.
66.
SalemJEAlexandreJBachelotA, et al. (2016) Influence of steroid hormones on ventricular repolarization. Pharmacol Ther167: 38–47.
67.
SandhuRKJimenezMCChiuveSE, et al. (2012) Smoking, smoking cessation, and risk of sudden cardiac death in women. Circ Arrhythm Electrophysiol5: 1091–1097.
68.
SeemanMV (2010) Schizophrenia: women bear a disproportionate toll of antipsychotic side effects. J Am Psychiatr Nurses Assoc16: 21–29.
69.
SimonGEStewartCYarboroughBJ, et al. (2018) Mortality rates after the first diagnosis of psychotic disorder in adolescents and young adults. JAMA Psychiatry75: 254–260.
70.
SmithDJLanganJMcLeanG, et al. (2013) Schizophrenia is associated with excess multiple physical-health comorbidities but low levels of recorded cardiovascular disease in primary care: cross-sectional study. BMJ Open3: e002808.
71.
StrausSMBleuminkGSDielemanJP, et al. (2004) Antipsychotics and the risk of sudden cardiac death. Arch Intern Med164: 1293–1297.
72.
StrausSMKorsJADe BruinML, et al. (2006) Prolonged QTc interval and risk of sudden cardiac death in a population of older adults. J Am Coll Cardiol47: 362–367.
73.
SumicJCBaricVBilicP, et al. (2007) QTc and psychopharmacs: are there any differences between monotherapy and polytherapy. Ann Gen Psychiatry6: 13.
74.
TirupatiSGulatiS (2022) Electrocardiographic abnormalities and psychotropic polypharmacy in schizophrenia and schizoaffective disorders. Australas Psychiatry30: 243–246.
75.
TisdaleJE (2016) Drug-induced QT interval prolongation and torsades de pointes: role of the pharmacist in risk assessment, prevention and management. Can Pharm J (Ott)149: 139–152.
76.
TrinkleyKEPageRL2ndLienH, et al. (2013) QT interval prolongation and the risk of torsades de pointes: essentials for clinicians. Curr Med Res Opin29: 1719–1726.
77.
van NoordCDörrMSturkenboomMC, et al. (2010) The association of serum testosterone levels and ventricular repolarization. Eur J Epidemiol25: 21–28.
78.
WannametheeGShaperAGMacfarlanePW, et al. (1995) Risk factors for sudden cardiac death in middle-aged British men. Circulation91: 1749–1756.
Wenzel-SeifertKWittmannMHaenE (2011) QTc prolongation by psychotropic drugs and the risk of Torsade de Pointes. Dtsch Arztebl Int108: 687–693.
81.
XiangY-TChiuHFKUngvariGS, et al. (2015) QTc prolongation in schizophrenia patients in Asia: clinical correlates and trends between 2004 and 2008/2009. Human Psychopharmacology-Clinical and Experimental30: 94–99.
82.
YangFDWangXQLiuXP, et al. (2011) Sex difference in QTc prolongation in chronic institutionalized patients with schizophrenia on long-term treatment with typical and atypical antipsychotics. Psychopharmacology (Berl)216: 9–16.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
